Clinical Trial Update: A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing TLL-018 to tofacitinib in rheumatoid arthritis patients with inadequate response or intolerance to bDMARDs is ongoing or not yet compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• TLL-018
• Tofacitinib (tofacitinib)

Snippet

Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd | Conditions: Rheumatoid Arthritis | Phase 3 | Status: UNKNOWN